| Literature DB >> 20706691 |
Clara Menéndez1, Xavier Castellsagué, Montse Renom, Jahit Sacarlal, Llorenç Quintó, Belen Lloveras, Joellen Klaustermeier, Janet R Kornegay, Betuel Sigauque, F Xavier Bosch, Pedro L Alonso.
Abstract
There is limited information on the prevalence of sexually transmitted infections and the prevalence of cervical neoplasia in rural sub-Saharan Africa. This study describes the prevalence and the etiology of STIs and the prevalence of cervical neoplasia among women in southern Mozambique. An age-stratified cross-sectional study was performed where 262 women aged 14 to 61 years were recruited at the antenatal clinic (59%), the family-planning clinic (7%), and from the community (34%). At least one active STI was diagnosed in 79% of women. Trichomonas vaginalis was present in 31% of all study participants. The prevalence of Neisseria gonorrhea and Chlamydia trachomatis were 14% and 8%, respectively, and Syphilis was diagnosed in 12% of women. HPV DNA was detected in 40% of women and cervical neoplasia was diagnosed in 12% of all women. Risk factors associated with the presence of some of the STIs were being divorced or widowed, having more than one sexual partner and having the partner living in another area. A higher prevalence was observed in the reproductive age group and some of the STIs were more frequently diagnosed in pregnant women. STI control programs are a priority to reduce the STIs burden, including HIV and cervical neoplasia.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20706691 PMCID: PMC2913799 DOI: 10.1155/2010/609315
Source DB: PubMed Journal: Infect Dis Obstet Gynecol ISSN: 1064-7449
Characteristics of the study women.
|
| % | ||
|---|---|---|---|
| Age group | 14–20 | 51 | 19 |
| 21–30 | 62 | 24 | |
| 31–40 | 54 | 21 | |
| 41–50 | 53 | 20 | |
| 51–61 | 42 | 16 | |
|
| |||
| Ethnic group | Shangana | 208 | 79 |
| Other | 54 | 21 | |
|
| |||
| Education | Reads and/or writes | 81 | 31 |
| Neither reads nor writes | 181 | 69 | |
|
| |||
| Marital status | Never married | 20 | 8 |
| Currently married | 212 | 81 | |
| Divorced or widowed | 30 | 11 | |
|
| |||
| Number of women living with husband | 1 | 185 | 71 |
| >1 | 72 | 27 | |
| Unknown | 5 | 2 | |
|
| |||
| Husband's job | Farmer | 59 | 23 |
| Driver | 8 | 3 | |
| Miner | 51 | 19 | |
| Manual worker | 44 | 17 | |
| Shop keeper | 7 | 3 | |
| Civil servant | 10 | 4 | |
| Other | 45 | 17 | |
| Unknown | 38 | 15 | |
|
| |||
| Husband's place of residence | Manhiça | 133 | 51 |
| Maputo | 27 | 10 | |
| South Africa | 52 | 20 | |
| Unknown | 50 | 19 | |
|
| |||
| Parity | None | 46 | 18 |
| 1 | 29 | 11 | |
| 2 to 5 | 99 | 38 | |
| >5 | 85 | 32 | |
| Unknown | 3 | 1 | |
|
| |||
| Pregnant now | No | 111 | 42 |
| Yes | 151 | 58 | |
|
| |||
| Age at first sexual intercourse | 12–15 | 52 | 20 |
| 16-17 | 43 | 16 | |
| 18–20 | 26 | 10 | |
| Unknown | 141 | 54 | |
|
| |||
| Number of sexual partners in lifetime | Never had | 3 | 1 |
| 1 | 149 | 57 | |
| >1 | 103 | 39 | |
| Unknown | 7 | 3 | |
Prevalence of STIs and cervical neoplasia in women from Manhiça, Mozambique.
|
| Prevalence (%) | 95% Confidence interval | |
|---|---|---|---|
| Gonococcal infection | 34/250 | 14 | (10; 19) |
| Syphilis (RPR & IgG) | 31/258 | 12 | (8; 17) |
| HPV DNA | 100/253 | 40 | (33; 46) |
| HIV antibodies | 30/256 | 12 | (8; 16) |
| HSV-2 antibodies | 213/257 | 83 | (78; 87) |
| Chlamydia trachomatis | 19/253 | 8 | (5; 11) |
| Trichomona vaginalis | 78/254 | 31 | (25; 37) |
| HBsAg antibodies | 20/255 | 8 | (5; 12) |
| Anti-HBc antibodies | 160/256 | 63 | (56; 68) |
| Any treatable STI* | 128/252 | 51 | (44; 57) |
| Any active STI** | 179/254 | 70 | (64; 76) |
| Cervical neoplasia | 30/245 | 12 | (8; 17) |
*Any treatable STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis or chlamydia trachomatis.
**Any active STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis, chlamydia trachomatis, HPV or HIV infection.
Figure 1Seroprevalence of syphilis, HIV and HSV-2 (a) and prevalence of gonococcal, HPV, trichomonal and chlamydia trachomatis (CT) infections (b).
Significant variables according to the multivariate analysis of risk factors for STIs and cervical neoplasia.
| Infection | Variable | Multivariate OR* | (95% CI) |
| |
|---|---|---|---|---|---|
| Gonococcal infection | Number of sexual partners | 1 | 1 | .014 | |
| >1 | 2.8 | (1.2; 6.2) | |||
|
| |||||
| Syphilis (RPR & IgG) | HPV | No | 1 | .005 | |
| Yes | 3.2 | (1.4; 7.5) | |||
|
| |||||
| Syphilis (RPR & IgG) | Marital status | Never married | 1 | .005 | |
| Married now | 0.7 | (0.1; 3.9) | |||
| Divorced or widowed | 3.6 | (0.6; 21.9) | |||
|
| |||||
| HPV | Cervical neoplasia | No | 1 | <.0001 | |
| Yes | 9.8 | (3.7; 26.3) | |||
| Unknown | 2.7 | (0.6; 12.0) | |||
|
| |||||
| HPV | RPR | No | 1 | <.0001 | |
| Yes | 4.1 | (1.9; 9.1) | |||
|
| |||||
| HPV | Anogenital warts | No | 1 | .054 | |
| Yes | 4.2 | (1.0; 17.8) | |||
|
| |||||
| HIV | Marital status | Never married | 1 | .005 | |
| Married now | 0.5 | (0.1; 2.3) | |||
| Divorced or widowed | 2.7 | (0.5; 16.0) | |||
|
| |||||
| HIV | Parity | None | 1 | .02 | |
| 1 child | 0.7 | (0.1; 3.6) | |||
| 2 to 5 | 0.6 | (0.1; 3.0) | |||
| more than 5 | 4.3 | (0.7; 26.9) | |||
|
| |||||
| HSV-2 | Age at first child | Never had | 1 | .014 | |
| 13–18 | 3.7 | (1.1; 12.9) | |||
| 19 | 48.7 | (3.0; 792.7) | |||
| 20–28 | 27.3 | (3.1; 241.2) | |||
| Unknown | 2.3 | (0.5; 9.7) | |||
|
| |||||
| HSV-2 | Selection of women | Antenatal clinic | 1 | .006 | |
| Family planning | 0.1 | (0.0; 0.8) | |||
| Other | 0 | (0.0; 0.3) | |||
|
| |||||
| Trichomona vaginalis | Husband's place of residence | Manhiça | 1 | .002 | |
| Maputo | 2.5 | (1.0; 6.3) | |||
| South Africa | 1.2 | (0.6; 2.4) | |||
| Unknown | 0.2 | (0.1; 0.6) | |||
|
| |||||
| Trichomona vaginalis | Anogenital warts | No | 1 | .018 | |
| Yes | 7.1 | (1.4; 36.5) | |||
|
| |||||
| HBsAg | Number of women living with husband | 1 | 1 | .028 | |
| >1 | 0.1 | (0.0; 0.8) | |||
|
| |||||
| Any treatable STI# | Anogenital warts | No | 1 | .007 | |
| Yes | 11 | (1.9; 63.1) | |||
|
| |||||
| Any active STI## | HSV-2 antibodies | No | 1 | .0029 | |
| Yes | 2.4 | (1.1; 5.4) | |||
|
| |||||
| Any active STI## | Chlamydia trachomatis | No | 1 | .042 | |
| Yes | 2.3 | (1.0; 5.1) | |||
|
| |||||
| Cervical neoplasia | HPV | No | 1 | <.0001 | |
| Yes | 10.1 | (3.7; 27.5) | |||
|
| |||||
| Cervical neoplasia | RPR | No | 1 | .068 | |
| Yes | 0.2 | (0.1; 1.1) | |||
*Adjusted by age and ethnic group.
**Likelihood Ratio Test versus model with variable removed.
#Any treatable STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis or Chlamydia trachomatis.
##Any active STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis, Chlamydia trachomatis, HPV or HIV infection.
Prevalence and risk of STIs and cervical neoplasia by HIV status.
| STD by HIV | HIV (−) | HIV (+) | Adjusted* OR | 95% Cl |
| ||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
|
| % |
| % | ||||
| Gonococcal infection | 27 | 12 | 6 | 20 | 1.9 | (0.7; 5.5) | .219 |
| Syphilis (RPR & IgG) | 26 | 12 | 5 | 17 | 1.6 | (0.5; 4.5) | .408 |
| HPV DNA | 83 | 37 | 14 | 47 | 1.6 | (0.7; 3.5) | .262 |
| HSV-2 antibodies | 185 | 82 | 27 | 90 | 2.1 | (0.6; 7.6) | .259 |
| Chlamydia trachomatis DNA | 14 | 6 | 5 | 17 | 3.1 | (1.0; 9.6) | .051 |
| Trichomona vaginalis | 67 | 30 | 9 | 30 | 1.0 | (0.4; 2.4) | .966 |
| HBsAg anribodies | 19 | 8 | 1 | 3 | 0.4 | (0.1; 3.0) | .359 |
| Anti-HBc antibodies | 137 | 61 | 22 | 73 | 1.8 | (0.8; 4.3) | .172 |
| Any treatable STI** | 107 | 47 | 18 | 60 | 1.7 | (0.8; 3.8) | .190 |
| Cervical neoplasia | 23 | 10 | 6 | 20 | 2.5 | (0.9; 7.0) | .088 |
*Adjusted by age and ethnic group.
**Any treatable STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis or chlamydia trachomatis.